Vopratelimab for Malignancies

Phase-Based Progress Estimates
Vopratelimab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is for people with cancer who have participated in a previous study of the drug vopratelimab. The trial will provide continued access to the drug for these people.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 48 months

48 months
% subjects with adverse events (AEs)
% subjects with clinically significant change from baseline in clinical laboratory tests
% subjects with serious adverse events (SAEs)
Median progression free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Vopratelimab with ipilimumab
1 of 3
1 of 3
Vopratelimab with nivolumab
1 of 3

Experimental Treatment

4 Total Participants · 3 Treatment Groups

Primary Treatment: Vopratelimab · No Placebo Group · Phase 1 & 2

Vopratelimab with ipilimumabExperimental Group · 2 Interventions: Vopratelimab, Ipilimumab · Intervention Types: Drug, Drug
Experimental Group · 1 Intervention: Vopratelimab · Intervention Types: Drug
Vopratelimab with nivolumabExperimental Group · 2 Interventions: Nivolumab, Vopratelimab · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
Not yet FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 months

Who is running the clinical trial?

Jounce Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
677 Total Patients Enrolled
4 Trials studying Malignancies
602 Patients Enrolled for Malignancies
Ellen Hooper, MDStudy DirectorJounce Therapeutics, Inc.
2 Previous Clinical Trials
136 Total Patients Enrolled
1 Trials studying Malignancies
61 Patients Enrolled for Malignancies

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are of child-bearing potential and you or your partner agree to use adequate birth control throughout your participation and for 5 months following the last study treatment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.